Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents

Population level survival of patients with myelodysplastic syndromes (MDS) treated with hypomethylating agents (HMA) is inferior to clinical trials. Using SEER-Medicare data, we identified 2,086 MDS patients diagnosed in 2004–13, aged ≥66 years at diagnosis, and receiving ≥1 HMA cycle. We used multi...

Full description

Saved in:
Bibliographic Details
Published in:Leuk Lymphoma
Main Authors: Zeidan, Amer M., Hu, Xin, Zhu, Weiwei, Stahl, Maximilian, Wang, Rong, Huntington, Scott F., Giri, Smith, Bewersdorf, Jan Philipp, Podoltsev, Nikolai A., Gore, Steven D., Ma, Xiaomei, Davidoff, Amy J.
Format: Artigo
Language:Inglês
Published: 2019
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7732188/
https://ncbi.nlm.nih.gov/pubmed/31570040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1663423
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items